<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665286</url>
  </required_header>
  <id_info>
    <org_study_id>2015-5903</org_study_id>
    <nct_id>NCT02665286</nct_id>
  </id_info>
  <brief_title>Orphenadrine and Methocarbamol for LBP</brief_title>
  <official_title>Methocarbamol and Orphenadrine for Acute, Non-traumatic, Non-radicular Low Back Pain: A Randomized, Placebo Controlled, 3-armed Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low back pain is a common cause of visit to emergency department. It is not clear if skeletal
      muscle relaxants are of benefit for patients with acute low back pain. This is a randomized
      study to determine if skeletal muscle relaxants, when combined with naproxen, improve
      outcomes more than naproxen alone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute, non-traumatic, non-radicular low back pain will be enrolled at the time
      of discharge from the emergency department. Participants will be followed by telephone one
      week and 3 months after the ED visit
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Impairment as Measured on the Roland Morris Disability Questionnaire</measure>
    <time_frame>1 week</time_frame>
    <description>Change in Roland Morris Disability Questionnaire between baseline and 1 week.
The low back pain functional disability scale is the RMDQ. The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cases of Moderate or Severe LBP</measure>
    <time_frame>1 week</time_frame>
    <description>Participants with moderate to severe low back pain after treatment as report on the following ordinal scale: severe, moderate, mild, or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medications--Patient Self Report of Medication Use</measure>
    <time_frame>1 week</time_frame>
    <description>Participants still using medication such as analgesics for LBP after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Treatment</measure>
    <time_frame>1 week</time_frame>
    <description>The number of participants with affirmative response to the following question: Do you want the same medication combination during a subsequent episode of LBP. This is a patient-centered outcome that allows each individual to determine the desirability of the intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Naproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orphenadrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methocarbamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orphenadrine</intervention_name>
    <description>Orphenadrine 100mg PO BID x 7 days</description>
    <arm_group_label>Orphenadrine</arm_group_label>
    <other_name>anticholinergic drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methocarbamol</intervention_name>
    <description>Methocarbamol 750mg 1-2 tabs po TID x 7 days</description>
    <arm_group_label>Methocarbamol</arm_group_label>
    <other_name>Muscle relaxant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Naproxen 500mg PO BID x 7 days</description>
    <arm_group_label>Methocarbamol</arm_group_label>
    <arm_group_label>Orphenadrine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>nonsteroidal anti-inflammatory drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LBP duration &lt;= 2 weeks

          -  No trauma to low back within previous month

          -  No radicular symptoms

          -  No history of low back pain or history of only infrequent episodes

        Exclusion Criteria:

          -  Medication allergies or contra-indications

          -  Not available for follow-up

          -  Chronic pain syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin W Friedman, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <results_first_submitted>April 30, 2018</results_first_submitted>
  <results_first_submitted_qc>May 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2018</results_first_posted>
  <last_update_submitted>May 29, 2018</last_update_submitted>
  <last_update_submitted_qc>May 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Orphenadrine</mesh_term>
    <mesh_term>Methocarbamol</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Cholinergic Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02665286/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Naproxen 500mg po BID x 10 days #20 + Placebo
Naproxen: Naproxen 500mg PO BID x 7 days
Placebo: 1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days</description>
        </group>
        <group group_id="P2">
          <title>Orphenadrine</title>
          <description>Naproxen 500mg po BID x 10 days #20 + Orphenadrine
Orphenadrine: Orphenadrine 100mg PO BID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
        </group>
        <group group_id="P3">
          <title>Methocarbamol</title>
          <description>Naproxen 500mg po BID x 10 days #20 + Methocarbamol
Methocarbamol: Methocarbamol 750mg 1-2 tabs po TID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Naproxen 500mg po BID x 10 days #20 + Placebo
Naproxen: Naproxen 500mg PO BID x 7 days
Placebo: 1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days</description>
        </group>
        <group group_id="B2">
          <title>Orphenadrine</title>
          <description>Naproxen 500mg po BID x 10 days #20 + Orphenadrine
Orphenadrine: Orphenadrine 100mg PO BID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
        </group>
        <group group_id="B3">
          <title>Methocarbamol</title>
          <description>Naproxen 500mg po BID x 10 days #20 + Methocarbamol
Methocarbamol: Methocarbamol 750mg 1-2 tabs po TID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="81"/>
                    <count group_id="B4" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="12"/>
                    <measurement group_id="B2" value="40" spread="12"/>
                    <measurement group_id="B3" value="38" spread="12"/>
                    <measurement group_id="B4" value="39" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="81"/>
                    <count group_id="B4" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="81"/>
                    <count group_id="B4" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Back Pain Prior to Study</title>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="81"/>
                    <count group_id="B4" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="24" upper_limit="108"/>
                    <measurement group_id="B2" value="72" lower_limit="24" upper_limit="96"/>
                    <measurement group_id="B3" value="48" lower_limit="24" upper_limit="120"/>
                    <measurement group_id="B4" value="48" lower_limit="24" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Functional Impairment as Measured on the Roland Morris Disability Questionnaire</title>
        <description>Change in Roland Morris Disability Questionnaire between baseline and 1 week.
The low back pain functional disability scale is the RMDQ. The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Placebo
Naproxen: Naproxen 500mg PO BID x 7 days
Placebo: 1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Orphenadrine</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Orphenadrine
Orphenadrine: Orphenadrine 100mg PO BID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Methocarbamol</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Methocarbamol
Methocarbamol: Methocarbamol 750mg 1-2 tabs po TID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Impairment as Measured on the Roland Morris Disability Questionnaire</title>
          <description>Change in Roland Morris Disability Questionnaire between baseline and 1 week.
The low back pain functional disability scale is the RMDQ. The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="8.9" upper_limit="12.9"/>
                    <measurement group_id="O2" value="9.4" lower_limit="7.4" upper_limit="11.5"/>
                    <measurement group_id="O3" value="8.1" lower_limit="6.1" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cases of Moderate or Severe LBP</title>
        <description>Participants with moderate to severe low back pain after treatment as report on the following ordinal scale: severe, moderate, mild, or none</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Placebo
Naproxen: Naproxen 500mg PO BID x 7 days
Placebo: 1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Orphenadrine</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Orphenadrine
Orphenadrine: Orphenadrine 100mg PO BID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Methocarbamol</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Methocarbamol
Methocarbamol: Methocarbamol 750mg 1-2 tabs po TID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Cases of Moderate or Severe LBP</title>
          <description>Participants with moderate to severe low back pain after treatment as report on the following ordinal scale: severe, moderate, mild, or none</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medications--Patient Self Report of Medication Use</title>
        <description>Participants still using medication such as analgesics for LBP after treatment</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Placebo
Naproxen: Naproxen 500mg PO BID x 7 days
Placebo: 1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Orphenadrine</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Orphenadrine
Orphenadrine: Orphenadrine 100mg PO BID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Methocarbamol</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Methocarbamol
Methocarbamol: Methocarbamol 750mg 1-2 tabs po TID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Medications--Patient Self Report of Medication Use</title>
          <description>Participants still using medication such as analgesics for LBP after treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Treatment</title>
        <description>The number of participants with affirmative response to the following question: Do you want the same medication combination during a subsequent episode of LBP. This is a patient-centered outcome that allows each individual to determine the desirability of the intervention.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Placebo
Naproxen: Naproxen 500mg PO BID x 7 days
Placebo: 1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Orphenadrine</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Orphenadrine
Orphenadrine: Orphenadrine 100mg PO BID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Methocarbamol</title>
            <description>Naproxen 500mg po BID x 10 days #20 + Methocarbamol
Methocarbamol: Methocarbamol 750mg 1-2 tabs po TID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Treatment</title>
          <description>The number of participants with affirmative response to the following question: Do you want the same medication combination during a subsequent episode of LBP. This is a patient-centered outcome that allows each individual to determine the desirability of the intervention.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week after treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Naproxen 500mg po BID x 10 days #20 + Placebo
Naproxen: Naproxen 500mg PO BID x 7 days
Placebo: 1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days</description>
        </group>
        <group group_id="E2">
          <title>Orphenadrine</title>
          <description>Naproxen 500mg po BID x 10 days #20 + Orphenadrine
Orphenadrine: Orphenadrine 100mg PO BID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
        </group>
        <group group_id="E3">
          <title>Methocarbamol</title>
          <description>Naproxen 500mg po BID x 10 days #20 + Methocarbamol
Methocarbamol: Methocarbamol 750mg 1-2 tabs po TID x 7 days
Naproxen: Naproxen 500mg PO BID x 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>dizz</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin W. Friedman, MD, MS</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>(718)920-6266</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

